Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Syros Pharmaceuticals, Inc. (SYRS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 9.9% stake in Syros Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Bain Capital Life Sciences Fund II, L.P. has filed a Schedule 13D for Syros Pharmaceuticals, Inc. |
| 11/10/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 04/11/2022 |
SC 13G/A
| FMR LLC reports a 9.3% stake in SYROS PHARMACEUTICALS INC |
| 02/14/2022 |
SC 13G/A
| Bain Capital Life Sciences Fund II, L.P. has filed a Schedule 13D for Syros Pharmaceuticals, Inc. |
| 02/14/2022 |
SC 13G/A
| Nikko Asset Management Americas, Inc. reports a 0% stake in Syros Pharmaceuticals, Inc. |
| 02/11/2022 |
SC 13G/A
| Ally Bridge MedAlpha Master Fund L.P. reports a 6.3% stake in Syros Pharmaceuticals, Inc. |
| 02/09/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/04/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/03/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 03/10/2021 |
SC 13G/A
| ARK Investment Management LLC reports a 13.9% stake in Syros Pharmaceuticals, Inc. |
| 02/16/2021 |
SC 13G/A
| ARK Investment Management LLC reports a 19.7% stake in Syros Pharmaceuticals, Inc. |
| 02/16/2021 |
SC 13G/A
| Point72 Asset Management, L.P. reports a |
| 02/11/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/08/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/05/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/02/2021 |
SC 13G/A
| ARCH Venture Fund VII, L.P. has filed a Schedule 13D for – Exit Filing)* Syros Pharmaceuticals, Inc. |
| 02/01/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 10/09/2020 |
SC 13G/A
| ARK Investment Management LLC reports a 24.5% stake in Syros Pharmaceuticals, Inc. |
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2020 |
SC 13G/A
| Arch Venture Fund VII LP reports a 7.9% stake in Syros Pharmaceuticals, Inc. |
| 02/12/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/12/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/07/2020 |
SC 13G/A
| FMR LLC reports a 15% stake in SYROS PHARMACEUTICALS INC |
| 05/10/2019 |
SC 13G/A
| BlackRock Inc. reports a 4.9% stake in Syros Pharmaceuticals, Inc. |
| 02/14/2019 |
SC 13G/A
| Arch Venture Fund VII LP reports a 13.8% stake in Syros Pharmaceuticals, Inc. |
| 02/13/2019 |
SC 13G/A
| FMR LLC reports a 15% stake in SYROS PHARMACEUTICALS INC |
| 02/14/2018 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2018 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/02/2018 |
SC 13G/A
| Arch Venture Fund VII LP reports a 17.7% stake in Syros Pharmaceuticals, Inc. |
| 02/14/2017 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals [Amend] |
| 02/14/2017 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals [Amend] |
| 02/13/2017 |
SC 13G/A
| Syros Pharmaceuticals, Inc. reports a 19.8% stake in Syros Pharmaceuticals, Inc. |
|
|